Financhill
Sell
17

MNPR Quote, Financials, Valuation and Earnings

Last price:
$29.48
Seasonality move :
-9.44%
Day range:
$28.24 - $34.86
52-week range:
$1.72 - $54.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.33x
Volume:
42.4K
Avg. volume:
35.7K
1-year change:
839.85%
Market cap:
$183.4M
Revenue:
--
EPS (TTM):
-$1.99

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
MNPR
Monopar Therapeutics
-- -$0.62 -- -24% $58.69
CATX
Perspective Therapeutics
$123.2K -$0.31 -- -35.77% $14.39
ELMD
Electromed
$16.6M -- 13.91% -- $37.00
MYO
Myomo
$10.9M -$0.06 145.61% -24% $9.25
VNRX
VolitionRX
$1.3M -$0.04 222.77% -56.25% $3.03
XTNT
Xtant Medical Holdings
$32.3M -$0.02 9.96% -33.33% $1.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
MNPR
Monopar Therapeutics
$30.00 $58.69 $183.4M -- $0.00 0% --
CATX
Perspective Therapeutics
$1.80 $14.39 $133.3M -- $0.00 0% 11.65x
ELMD
Electromed
$22.39 $37.00 $191.6M 29.85x $0.00 0% 3.36x
MYO
Myomo
$4.35 $9.25 $149.6M -- $0.00 0% 5.05x
VNRX
VolitionRX
$0.53 $3.03 $52.3M -- $0.00 0% 37.34x
XTNT
Xtant Medical Holdings
$0.47 $1.75 $65.4M -- $0.00 0% 0.54x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
MNPR
Monopar Therapeutics
-- 3.962 -- --
CATX
Perspective Therapeutics
-- -2.375 -- --
ELMD
Electromed
-- 1.939 -- 4.68x
MYO
Myomo
-- 2.090 -- 2.82x
VNRX
VolitionRX
-28.76% 0.042 8.83% 0.19x
XTNT
Xtant Medical Holdings
44.29% 0.123 55.45% 0.94x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
MNPR
Monopar Therapeutics
-- -$1.6M -- -- -- -$1.1M
CATX
Perspective Therapeutics
-- -$20.9M -- -- -- -$41.2M
ELMD
Electromed
$12.6M $2.5M 15.91% 15.91% 15.64% $2.9M
MYO
Myomo
$8.6M -$245.3K -48.64% -48.64% -2.03% $2.5M
VNRX
VolitionRX
-- -$5.8M -- -- -1217.88% -$5.5M
XTNT
Xtant Medical Holdings
$16M -$1.9M -21.41% -35.34% -6.38% -$7K

Monopar Therapeutics vs. Competitors

  • Which has Higher Returns MNPR or CATX?

    Perspective Therapeutics has a net margin of -- compared to Monopar Therapeutics's net margin of --. Monopar Therapeutics's return on equity of -- beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MNPR
    Monopar Therapeutics
    -- -$0.37 --
    CATX
    Perspective Therapeutics
    -- -$0.61 --
  • What do Analysts Say About MNPR or CATX?

    Monopar Therapeutics has a consensus price target of $58.69, signalling upside risk potential of 95.64%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 743.25%. Given that Perspective Therapeutics has higher upside potential than Monopar Therapeutics, analysts believe Perspective Therapeutics is more attractive than Monopar Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MNPR
    Monopar Therapeutics
    1 1 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is MNPR or CATX More Risky?

    Monopar Therapeutics has a beta of 1.005, which suggesting that the stock is 0.519% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

  • Which is a Better Dividend Stock MNPR or CATX?

    Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MNPR or CATX?

    Monopar Therapeutics quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Monopar Therapeutics's net income of -$1.3M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 11.65x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MNPR
    Monopar Therapeutics
    -- -- -- -$1.3M
    CATX
    Perspective Therapeutics
    11.65x -- -- -$40.2M
  • Which has Higher Returns MNPR or ELMD?

    Electromed has a net margin of -- compared to Monopar Therapeutics's net margin of 12.11%. Monopar Therapeutics's return on equity of -- beat Electromed's return on equity of 15.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    MNPR
    Monopar Therapeutics
    -- -$0.37 --
    ELMD
    Electromed
    77.68% $0.22 $43.6M
  • What do Analysts Say About MNPR or ELMD?

    Monopar Therapeutics has a consensus price target of $58.69, signalling upside risk potential of 95.64%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 65.25%. Given that Monopar Therapeutics has higher upside potential than Electromed, analysts believe Monopar Therapeutics is more attractive than Electromed.

    Company Buy Ratings Hold Ratings Sell Ratings
    MNPR
    Monopar Therapeutics
    1 1 0
    ELMD
    Electromed
    2 0 0
  • Is MNPR or ELMD More Risky?

    Monopar Therapeutics has a beta of 1.005, which suggesting that the stock is 0.519% more volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.

  • Which is a Better Dividend Stock MNPR or ELMD?

    Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MNPR or ELMD?

    Monopar Therapeutics quarterly revenues are --, which are smaller than Electromed quarterly revenues of $16.3M. Monopar Therapeutics's net income of -$1.3M is lower than Electromed's net income of $2M. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while Electromed's PE ratio is 29.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 3.36x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MNPR
    Monopar Therapeutics
    -- -- -- -$1.3M
    ELMD
    Electromed
    3.36x 29.85x $16.3M $2M
  • Which has Higher Returns MNPR or MYO?

    Myomo has a net margin of -- compared to Monopar Therapeutics's net margin of -2.16%. Monopar Therapeutics's return on equity of -- beat Myomo's return on equity of -48.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    MNPR
    Monopar Therapeutics
    -- -$0.37 --
    MYO
    Myomo
    71.39% -$0.01 $24.7M
  • What do Analysts Say About MNPR or MYO?

    Monopar Therapeutics has a consensus price target of $58.69, signalling upside risk potential of 95.64%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 112.64%. Given that Myomo has higher upside potential than Monopar Therapeutics, analysts believe Myomo is more attractive than Monopar Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MNPR
    Monopar Therapeutics
    1 1 0
    MYO
    Myomo
    3 0 0
  • Is MNPR or MYO More Risky?

    Monopar Therapeutics has a beta of 1.005, which suggesting that the stock is 0.519% more volatile than S&P 500. In comparison Myomo has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.752%.

  • Which is a Better Dividend Stock MNPR or MYO?

    Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MNPR or MYO?

    Monopar Therapeutics quarterly revenues are --, which are smaller than Myomo quarterly revenues of $12.1M. Monopar Therapeutics's net income of -$1.3M is lower than Myomo's net income of -$260.1K. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 5.05x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MNPR
    Monopar Therapeutics
    -- -- -- -$1.3M
    MYO
    Myomo
    5.05x -- $12.1M -$260.1K
  • Which has Higher Returns MNPR or VNRX?

    VolitionRX has a net margin of -- compared to Monopar Therapeutics's net margin of -1226.82%. Monopar Therapeutics's return on equity of -- beat VolitionRX's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MNPR
    Monopar Therapeutics
    -- -$0.37 --
    VNRX
    VolitionRX
    -- -$0.07 -$17.8M
  • What do Analysts Say About MNPR or VNRX?

    Monopar Therapeutics has a consensus price target of $58.69, signalling upside risk potential of 95.64%. On the other hand VolitionRX has an analysts' consensus of $3.03 which suggests that it could grow by 469.23%. Given that VolitionRX has higher upside potential than Monopar Therapeutics, analysts believe VolitionRX is more attractive than Monopar Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MNPR
    Monopar Therapeutics
    1 1 0
    VNRX
    VolitionRX
    2 1 0
  • Is MNPR or VNRX More Risky?

    Monopar Therapeutics has a beta of 1.005, which suggesting that the stock is 0.519% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.463%.

  • Which is a Better Dividend Stock MNPR or VNRX?

    Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MNPR or VNRX?

    Monopar Therapeutics quarterly revenues are --, which are smaller than VolitionRX quarterly revenues of $474.5K. Monopar Therapeutics's net income of -$1.3M is higher than VolitionRX's net income of -$5.8M. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 37.34x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MNPR
    Monopar Therapeutics
    -- -- -- -$1.3M
    VNRX
    VolitionRX
    37.34x -- $474.5K -$5.8M
  • Which has Higher Returns MNPR or XTNT?

    Xtant Medical Holdings has a net margin of -- compared to Monopar Therapeutics's net margin of -10.04%. Monopar Therapeutics's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    MNPR
    Monopar Therapeutics
    -- -$0.37 --
    XTNT
    Xtant Medical Holdings
    50.85% -$0.02 $77.1M
  • What do Analysts Say About MNPR or XTNT?

    Monopar Therapeutics has a consensus price target of $58.69, signalling upside risk potential of 95.64%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 272.34%. Given that Xtant Medical Holdings has higher upside potential than Monopar Therapeutics, analysts believe Xtant Medical Holdings is more attractive than Monopar Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MNPR
    Monopar Therapeutics
    1 1 0
    XTNT
    Xtant Medical Holdings
    2 0 0
  • Is MNPR or XTNT More Risky?

    Monopar Therapeutics has a beta of 1.005, which suggesting that the stock is 0.519% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.341%.

  • Which is a Better Dividend Stock MNPR or XTNT?

    Monopar Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MNPR or XTNT?

    Monopar Therapeutics quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Monopar Therapeutics's net income of -$1.3M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Monopar Therapeutics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics is -- versus 0.54x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MNPR
    Monopar Therapeutics
    -- -- -- -$1.3M
    XTNT
    Xtant Medical Holdings
    0.54x -- $31.5M -$3.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is ROOT Stock the Next Big Thing?
Is ROOT Stock the Next Big Thing?

Root Holdings (NASDAQ:ROOT) is the parent company of Root Insurance,…

Is Okta a Good Stock to Buy?
Is Okta a Good Stock to Buy?

Okta (NASDAQ:OKTA) is used by some of the largest firms…

Is Fidelity High Dividend ETF a Good Investment Now?
Is Fidelity High Dividend ETF a Good Investment Now?

Fidelity’s High Dividend ETF (FDVV) is a fund that offers…

Stock Ideas

Sell
37
Is AAPL Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 31x

Sell
37
Is MSFT Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 30x

Sell
31
Is NVDA Stock a Buy?

Market Cap: $2.3T
P/E Ratio: 32x

Alerts

Sell
45
RGC alert for Apr 5

Regencell Bioscience Holdings [RGC] is up 32.59% over the past day.

Sell
25
GDXU alert for Apr 5

MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 27.33% over the past day.

Buy
76
SOXS alert for Apr 5

Direxion Daily Semiconductor Bear 3X Shares [SOXS] is up 23.96% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock